Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious ...

Global events can pose significant challenges to the supply of APIs, and thus the continuity of drug supply. Any disruption ...

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that ...

The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

There’s a new kid on the block in the fast-growing radiopharmaceuticals category, as Nucleus RadioPharma chalks up an oversubscribed Series A that raised $56 million that will be used to create ...

Join biotech commentators Daphne Zohar, Josh Schimmer, and Brad Loncar for a weekly discussion of all things biotech. From emerging trends and investment opportunities to the challenges facing the ...